Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment
Authors
Keywords
-
Journal
Biomarker Research
Volume 9, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-07-22
DOI
10.1186/s40364-021-00312-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
- (2021) Karthik Dhatchinamoorthy et al. Frontiers in Immunology
- Combining microenvironment normalization strategies to improve cancer immunotherapy
- (2020) Fotios Mpekris et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
- (2020) Rita Nanda et al. JAMA Oncology
- Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
- (2020) Paola Ciciola et al. Journal of Clinical Medicine
- Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo
- (2020) T. Karn et al. ANNALS OF ONCOLOGY
- Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)
- (2020) Shota Fukuoka et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- MHC-I genotype and tumor mutational burden predict response to immunotherapy
- (2020) Aaron M. Goodman et al. Genome Medicine
- PD-L1 protein expression on both tumor cells and macrophages are associated with response to neoadjuvant durvalumab in triple negative breast cancer (TNBC)
- (2020) Fahad Shabbir Ahmed et al. CLINICAL CANCER RESEARCH
- Efficacy of shear-wave elastography versus dynamic optical breast imaging for predicting the pathological response to neoadjuvant chemotherapy in breast cancer
- (2020) Jing Zhang et al. EUROPEAN JOURNAL OF RADIOLOGY
- Synergies of Antiangiogenic Therapy and Immune Checkpoint Blockade in Renal Cell Carcinoma: From Theoretical Background to Clinical Reality
- (2020) Xiaohan Zhou et al. Frontiers in Oncology
- Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity
- (2020) Won Suk Lee et al. EXPERIMENTAL AND MOLECULAR MEDICINE
- Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial
- (2020) Robert J. Motzer et al. NATURE MEDICINE
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
- (2020) Javier Cortes et al. LANCET
- Cancer‑associated fibroblast regulation of tumor neo‑angiogenesis as a therapeutic target in cancer (Review)
- (2019) Fang‑Tao Wang et al. Oncology Letters
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
- (2019) Vicky Makker et al. LANCET ONCOLOGY
- A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer – clinical results and biomarker analysis of GeparNuevo study
- (2019) S Loibl et al. ANNALS OF ONCOLOGY
- The Intersection between Tumor Angiogenesis and Immune Suppression
- (2019) Osama E. Rahma et al. CLINICAL CANCER RESEARCH
- Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
- (2019) Ming Yi et al. Molecular Cancer
- TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion
- (2019) Omar Khan et al. NATURE
- Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression
- (2019) Antonino Bruno et al. Frontiers in Immunology
- Dual PD ‐1 and VEGFR ‐2 blockade promotes vascular normalization and enhances anti‐tumor immune responses in HCC
- (2019) Kohei Shigeta et al. HEPATOLOGY
- STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade
- (2019) Hannah Yang et al. JOURNAL OF CLINICAL INVESTIGATION
- The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)
- (2019) Johanna C. Bendell et al. ONCOLOGIST
- LBA8_PRKEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)
- (2019) P Schmid et al. ANNALS OF ONCOLOGY
- VEGF-A drives TOX-dependent T cell exhaustion in anti–PD-1–resistant microsatellite stable colorectal cancers
- (2019) Chang Gon Kim et al. Science Immunology
- Myeloid-Derived Suppressor Cells: Major Figures that Shape the Immunosuppressive and Angiogenic Network in Cancer
- (2019) Eleni-Kyriaki Vetsika et al. Cells
- A Glial Signature and Wnt7 Signaling Regulate Glioma-Vascular Interactions and Tumor Microenvironment
- (2018) Amelie Griveau et al. CANCER CELL
- Increased vessel perfusion predicts the efficacy of immune checkpoint blockade
- (2018) Xichen Zheng et al. JOURNAL OF CLINICAL INVESTIGATION
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
- (2018) Kabir A. Khan et al. Nature Reviews Clinical Oncology
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting VEGF/VEGFR to Modulate Antitumor Immunity
- (2018) Ju Yang et al. Frontiers in Immunology
- Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy
- (2018) Adriana Albini et al. Frontiers in Immunology
- Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression
- (2018) Viktor Fleming et al. Frontiers in Immunology
- 72OAddition of durvalumab (Dur) upon progression to bevacizumab (Bev) maintenance in advanced HER2-negative (HERNEG) breast cancer (BC): Safety, efficacy and biomarkers
- (2018) M Quintela-Fandino et al. ANNALS OF ONCOLOGY
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD4 + T Cell Activation and Vascular Normalization: Two Sides of the Same Coin?
- (2017) Michele De Palma et al. IMMUNITY
- CDK4/6 inhibition triggers anti-tumour immunity
- (2017) Shom Goel et al. NATURE
- Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
- (2017) Lin Tian et al. NATURE
- Tumour ischaemia by interferon-γ resembles physiological blood vessel regression
- (2017) Thomas Kammertoens et al. NATURE
- Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma
- (2017) Lei Qin et al. NEURORADIOLOGY
- Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy
- (2017) B A Castro et al. ONCOGENE
- Role of vascular normalization in benefit from metronomic chemotherapy
- (2017) Fotios Mpekris et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade
- (2017) Martina Schmittnaegel et al. Science Translational Medicine
- Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
- (2017) Elizabeth Allen et al. Science Translational Medicine
- Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy
- (2017) Matthias Pinter et al. Science Translational Medicine
- Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers
- (2016) Florence T.H. Wu et al. CANCER RESEARCH
- Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells
- (2016) Naoki Horikawa et al. CLINICAL CANCER RESEARCH
- The urgent need to recover MHC class I in cancers for effective immunotherapy
- (2016) Federico Garrido et al. CURRENT OPINION IN IMMUNOLOGY
- Antiangiogenic therapy in oncology: current status and future directions
- (2016) Gordon C Jayson et al. LANCET
- Suppression of microRNA activity amplifies IFN-γ-induced macrophage activation and promotes anti-tumour immunity
- (2016) Caroline Baer et al. NATURE CELL BIOLOGY
- Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages
- (2016) Teresa E. Peterson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival
- (2016) Jonas Kloepper et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases
- (2016) N. N. Rahbari et al. Science Translational Medicine
- The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
- (2016) Vinit Kumar et al. TRENDS IN IMMUNOLOGY
- Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
- (2016) Jeffrey J. Wallin et al. Nature Communications
- Hypoxia-induced CCL28 promotes recruitment of regulatory T cells and tumor growth in liver cancer
- (2016) Li Ren et al. Oncotarget
- Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy
- (2016) Xinqi Wu et al. Cancer Immunology Research
- The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment
- (2016) Shona A. Hendry et al. Frontiers in Immunology
- Combining Radiation Therapy with Immune Checkpoint Blockade for Central Nervous System Malignancies
- (2016) Neil M. D’Souza et al. Frontiers in Oncology
- Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
- (2015) J. Naidoo et al. ANNALS OF ONCOLOGY
- CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice
- (2015) Yunching Chen et al. HEPATOLOGY
- Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
- (2015) William M. Sikov et al. JOURNAL OF CLINICAL ONCOLOGY
- VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors
- (2015) Thibault Voron et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8+ T cells
- (2015) Rafael Carretero et al. NATURE IMMUNOLOGY
- GPER in CAFs regulates hypoxia-driven breast cancer invasion in a CTGF-dependent manner
- (2015) JUAN REN et al. ONCOLOGY REPORTS
- Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients
- (2015) Sara M. Tolaney et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Intertwined regulation of angiogenesis and immunity by myeloid cells
- (2015) Lee B. Rivera et al. TRENDS IN IMMUNOLOGY
- Cancer-associated fibroblasts promote angiogenesis in gastric cancer through galectin-1 expression
- (2015) Dong Tang et al. TUMOR BIOLOGY
- Intratumoral Myeloid Cells Regulate Responsiveness and Resistance to Antiangiogenic Therapy
- (2015) Lee B. Rivera et al. Cell Reports
- Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: importance of myeloid-derived suppressor cells
- (2015) Svetlana Karakhanova et al. OncoImmunology
- Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer
- (2014) Nicole M Reusser et al. CANCER BIOLOGY & THERAPY
- Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
- (2014) Rakesh K. Jain CANCER CELL
- Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
- (2014) Gregory T Motz et al. NATURE MEDICINE
- Role of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade
- (2014) Nicolò Rigamonti et al. Cell Reports
- Orchestration of Angiogenesis by Immune Cells
- (2014) Antonino Bruno et al. Frontiers in Oncology
- The Impact of the Immune System on Tumor: Angiogenesis and Vascular Remodeling
- (2014) Christian Stockmann et al. Frontiers in Oncology
- Multicentre phase II trial of bevacizumab combined with docetaxel–carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905)
- (2013) H. R. Kim et al. ANNALS OF ONCOLOGY
- Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)
- (2013) B. Gerber et al. ANNALS OF ONCOLOGY
- Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy
- (2013) Y. Huang et al. CANCER RESEARCH
- Nab-Paclitaxel/Bevacizumab/Carboplatin Chemotherapy in First-Line Triple Negative Metastatic Breast Cancer
- (2013) Erika Hamilton et al. Clinical Breast Cancer
- Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy
- (2013) Y. Kienast et al. CLINICAL CANCER RESEARCH
- Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma
- (2013) Ana B. del Campo et al. INTERNATIONAL JOURNAL OF CANCER
- The tumor microenvironment at a glance
- (2013) F. R. Balkwill et al. JOURNAL OF CELL SCIENCE
- Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
- (2013) Rakesh K. Jain JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
- (2013) David Cameron et al. LANCET ONCOLOGY
- Combining two strategies to improve perfusion and drug delivery in solid tumors
- (2013) T. Stylianopoulos et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- ‘Cancer associated fibroblasts’ – more than meets the eye
- (2013) Shalom Madar et al. TRENDS IN MOLECULAR MEDICINE
- Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels
- (2013) Vikash P. Chauhan et al. Nature Communications
- Microvessel proliferation by co-expression of endothelial nestin and Ki-67 is associated with a basal-like phenotype and aggressive features in breast cancer
- (2012) K. Krüger et al. BREAST
- Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial
- (2012) Adam Brufsky et al. BREAST CANCER RESEARCH AND TREATMENT
- T-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis
- (2012) A. Facciabene et al. CANCER RESEARCH
- VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer
- (2012) M. Terme et al. CANCER RESEARCH
- Podoplanin expressing cancer associated fibroblasts are associated with unfavourable prognosis in adenocarcinoma of the esophagus
- (2012) Sebastian F. Schoppmann et al. CLINICAL & EXPERIMENTAL METASTASIS
- Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab
- (2012) P. S. Hegde et al. CLINICAL CANCER RESEARCH
- The discovery of placenta growth factor and its biological activity
- (2012) Sandro De Falco EXPERIMENTAL AND MOLECULAR MEDICINE
- Tumor-Expressed Inducible Nitric Oxide Synthase Controls Induction of Functional Myeloid-Derived Suppressor Cells through Modulation of Vascular Endothelial Growth Factor Release
- (2012) P. Jayaraman et al. JOURNAL OF IMMUNOLOGY
- TIMP-2 Targets Tumor-associated Myeloid Suppressor Cells With Effects in Cancer Immune Dysfunction and Angiogenesis
- (2012) Liliana Guedez et al. JOURNAL OF IMMUNOTHERAPY
- Macrophage plasticity and polarization in tissue repair and remodelling
- (2012) Alberto Mantovani et al. JOURNAL OF PATHOLOGY
- First-Line Bevacizumab-Containing Therapy for Triple-Negative Breast Cancer: Analysis of 585 Patients Treated in the ATHENA Study
- (2012) Christoph Thomssen et al. ONCOLOGY
- Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
- (2012) Y. Huang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia
- (2012) S. J. Conley et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma
- (2011) Jiankun Liu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Vascular proliferation is increased in basal-like breast cancer
- (2011) Hawa Nalwoga et al. BREAST CANCER RESEARCH AND TREATMENT
- Targeting the ANG2/TIE2 Axis Inhibits Tumor Growth and Metastasis by Impairing Angiogenesis and Disabling Rebounds of Proangiogenic Myeloid Cells
- (2011) Roberta Mazzieri et al. CANCER CELL
- A Role for Bone Morphogenetic Protein-4 in Lymph Node Vascular Remodeling and Primary Tumor Growth
- (2011) R. H. Farnsworth et al. CANCER RESEARCH
- Angiopoietin-2 TIEs Up Macrophages in Tumor Angiogenesis: Figure 1.
- (2011) Michele De Palma et al. CLINICAL CANCER RESEARCH
- Podoplanin expression by cancer-associated fibroblasts predicts poor outcome in invasive ductal breast carcinoma
- (2011) Bartosz Pula et al. HISTOPATHOLOGY
- High expression of Galectin-1 in pancreatic stellate cells plays a role in the development and maintenance of an immunosuppressive microenvironment in pancreatic cancer
- (2011) Dong Tang et al. INTERNATIONAL JOURNAL OF CANCER
- RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
- (2011) Nicholas J. Robert et al. JOURNAL OF CLINICAL ONCOLOGY
- M2 Macrophages Induced by Prostaglandin E2 and IL-6 from Cervical Carcinoma Are Switched to Activated M1 Macrophages by CD4+ Th1 Cells
- (2011) M. Heusinkveld et al. JOURNAL OF IMMUNOLOGY
- Angiopoietin 2 Stimulates TIE2-Expressing Monocytes To Suppress T Cell Activation and To Promote Regulatory T Cell Expansion
- (2011) Seth B. Coffelt et al. JOURNAL OF IMMUNOLOGY
- Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
- (2011) Andrea Facciabene et al. NATURE
- Tumor-infiltrating CD4+ Th17 cells produce IL-17 in tumor microenvironment and promote tumor progression in human gastric cancer
- (2011) Iwahashi ONCOLOGY REPORTS
- Endothelial focal adhesion kinase mediates cancer cell homing to discrete regions of the lungs via E-selectin up-regulation
- (2011) Sachie Hiratsuka et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The US FDAs withdrawal of the breast cancer indication for Avastin (bevacizumab)
- (2011) Larry D. Sasich et al. SAUDI PHARMACEUTICAL JOURNAL
- Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy
- (2010) V Goede et al. BRITISH JOURNAL OF CANCER
- Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer
- (2010) R. K. Shrimali et al. CANCER RESEARCH
- Macrophage Diversity Enhances Tumor Progression and Metastasis
- (2010) Bin-Zhi Qian et al. CELL
- Transforming growth factor-β and the hallmarks of cancer
- (2010) Maozhen Tian et al. CELLULAR SIGNALLING
- Angiopoietin-2 Interferes with Anti-VEGFR2-Induced Vessel Normalization and Survival Benefit in Mice Bearing Gliomas
- (2010) S.-S. Chae et al. CLINICAL CANCER RESEARCH
- Role of myeloid cells in vascular endothelial growth factor-independent tumor angiogenesis
- (2010) Napoleone Ferrara CURRENT OPINION IN HEMATOLOGY
- Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma
- (2010) Tracy T. Batchelor et al. JOURNAL OF CLINICAL ONCOLOGY
- Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
- (2010) Subhra K Biswas et al. NATURE IMMUNOLOGY
- PDGF-C Mediates the Angiogenic and Tumorigenic Properties of Fibroblasts Associated with Tumors Refractory to Anti-VEGF Treatment
- (2009) Yongping Crawford et al. CANCER CELL
- CD4+ T Cells Regulate Pulmonary Metastasis of Mammary Carcinomas by Enhancing Protumor Properties of Macrophages
- (2009) David G. DeNardo et al. CANCER CELL
- MMP13 as a stromal mediator in controlling persistent angiogenesis in skin carcinoma
- (2009) Wiltrud Lederle et al. CARCINOGENESIS
- Edema Control by Cediranib, a Vascular Endothelial Growth Factor Receptor–Targeted Kinase Inhibitor, Prolongs Survival Despite Persistent Brain Tumor Growth in Mice
- (2009) Walid S. Kamoun et al. JOURNAL OF CLINICAL ONCOLOGY
- Galectin-1-Mediated Tumor Invasion and Metastasis, Up-Regulated Matrix Metalloproteinase Expression, and Reorganized Actin Cytoskeletons
- (2009) M.-H. Wu et al. MOLECULAR CANCER RESEARCH
- Molecular biology of cancer-associated fibroblasts: Can these cells be targeted in anti-cancer therapy?
- (2009) Tamas A. Gonda et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- TGF-β signaling in vascular biology and dysfunction
- (2008) Marie-José Goumans et al. CELL RESEARCH
- Hypoxia-Adenosinergic Immunosuppression: Tumor Protection by T Regulatory Cells and Cancerous Tissue Hypoxia
- (2008) M. V. Sitkovsky et al. CLINICAL CANCER RESEARCH
- Dynamic optical breast imaging: A novel technique to detect and characterize tumor vessels
- (2008) Laure S. Fournier et al. EUROPEAN JOURNAL OF RADIOLOGY
- Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy
- (2008) Rafael Carretero et al. IMMUNOGENETICS
- Stat3 mediates myeloid cell–dependent tumor angiogenesis in mice
- (2008) Maciej Kujawski et al. JOURNAL OF CLINICAL INVESTIGATION
- Direct regulation of TWIST by HIF-1α promotes metastasis
- (2008) Muh-Hwa Yang et al. NATURE CELL BIOLOGY
- Orchestrating the orchestrators: chemokines in control of T cell traffic
- (2008) Shannon K Bromley et al. NATURE IMMUNOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started